Approval · Notice of Compliance 25279 · 2021
NAT-BENDAMUSTINE: Notice of Compliance 25279
Issued June 30, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25279
- Date
- June 30, 2021
- Company
- Natco Pharma (Canada) IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- TREANDA
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAT-BENDAMUSTINE | 02496887 | Marketed |
| NAT-BENDAMUSTINE | 02496895 | Marketed |
Medicinal ingredients
- BENDAMUSTINE HYDROCHLORIDE 25 MG per VIAL
- BENDAMUSTINE HYDROCHLORIDE 100 MG per VIAL